News Related to Center for Devices and Radiological Health

Related coverage linked through entity extraction aliases.

FDA Approves Optune Pax for Locally Advanced Pancreatic Cancer

May 21, 2026

The FDA approved Novocure’s Optune Pax, a wearable tumor-treating fields device, for pancreatic cancer in combination with chemotherapy. Phase III PANOVA-3 data showed delayed pain progression and improved one-year overall survival in inoperable locally advanced disease.

FDA Approves Optune Pax Device for Locally Advanced Pancreatic Cancer

Feb 13, 2026

The FDA has approved Optune Pax, a wearable device delivering tumor treating fields for locally advanced pancreatic cancer. The approval marks the first new treatment modality for this indication in nearly 30 years.